ALT screening for HCV should be dropped by blood banks, NIH panel says.
This article was originally published in The Gray Sheet
ALT SCREENING FOR HCV SHOULD BE DISCONTINUED BY BLOOD BANKS, a National Institutes of Health consensus panel concluded Jan. 11 in Bethesda, Maryland. The panel of physicians and researchers made its recommendation based on the low positive predictive value of alanine aminotransferase tests in detecting the hepatitis C virus, as well as the availability of improved, HCV-specific tests. The consensus development conference was sponsored by the National Heart, Lung and Blood Institute and chaired by Jane Desforges, MD, New England Medical Center, Boston.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.